{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(5)"],"submitter":["Yu X"],"pubmed_abstract":["<h4>Background</h4>Few large-scale studies have been published using real-world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)-mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit most from EGFR-tyrosine kinase inhibitors (TKIs). Our study aimed to assess whether EGFR-TKI treatment confers survival benefits among advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations in the Chinese population.<h4>Patients and methods</h4>A total of 6451 advanced NSCLC patients were diagnosed between January 1, 2013 and June 30, 2019 in Zhejiang Cancer Hospital. Ultimately, 2864 patients with a confirmed EGFR mutation genotype were enrolled in our study. OS was measur"],"journal":["Cancer medicine"],"pagination":["5630-5638"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10028166"],"repository":["biostudies-literature"],"pubmed_title":["The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study."],"pmcid":["PMC10028166"],"pubmed_authors":["Si J","Zhang X","Wei J","Wang Y","Ma T","Sun Y","Jin J","Yu X","Song Z"],"additional_accession":[]},"is_claimable":false,"name":"The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.","description":"<h4>Background</h4>Few large-scale studies have been published using real-world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)-mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit most from EGFR-tyrosine kinase inhibitors (TKIs). Our study aimed to assess whether EGFR-TKI treatment confers survival benefits among advanced non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations in the Chinese population.<h4>Patients and methods</h4>A total of 6451 advanced NSCLC patients were diagnosed between January 1, 2013 and June 30, 2019 in Zhejiang Cancer Hospital. Ultimately, 2864 patients with a confirmed EGFR mutation genotype were enrolled in our study. OS was measur","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-19T15:00:17.054Z","creation":"2025-04-19T15:00:17.054Z"},"accession":"S-EPMC10028166","cross_references":{"pubmed":["36380563"],"doi":["10.1002/cam4.5413"]}}